Early and Late Pulmonary and Systemic Inflammation in Critically Ill, Mechanically Ventilated Patients With Verified COVID-19
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Hvidovre University Hospital
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Lymphocyte populations
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The aim of the present study is to examine the inflammatory response in the pulmonary compartment and blood of critically ill patients admitted to the ICU with COVID-19.
Detailed Description
The mechanisms of the ARDS-like respiratory failure observed in patients with COVID-19 are currently unknown, but may be related to a distinct local immune response within the lung. In the present study, we will examine the cellular and humoral pulmonary immune response in mechanically ventilated patients admitted to the ICU with COVID-19 by examining immune cell profiles, cytokine patterns, and the complement pathway in bronchoalveolar lavage fluid, and relate it to the concomitant systemic inflammatory response. We will examine the patients on day 1-3 and 7-9 after ICU admission.
Investigators
Ronni R. Plovsing
MD, PhD
Hvidovre University Hospital
Eligibility Criteria
Inclusion Criteria
- •Age \> 18y
- •Mechanical ventilation
- •Verified COVID-19 (throat swab or tracheal aspirate positive for SARS-CoV-2)
- •ARDS according to the Berlin definition
Exclusion Criteria
- •Untreated malignant tachycardia or bradycardia
- •Suspected or verified intracranial hypertension (ICP \> 15 mmHg)
- •Unilateral lung ventilation
- •Severe non-correctable coagulopathy
Outcomes
Primary Outcomes
Lymphocyte populations
Time Frame: Day 7
Cell populations and subpopulations evaluated by 10 colored flow cytometry (B cells, T cells, TCR subsets, Tregs/Th17, dendritic cells, myeloid cells and neutrophils) in bronchoalveolar lavage fluid and blood
White blood cell counts
Time Frame: Day 7
Total white blood cells, neutrocytes, lymphocytes, and monocytes in bronchoalveolar lavage fluid and blood
Secondary Outcomes
- Cytokines(Day 7)
- Microorganisms(Up to 12 weeks)
- Levels of SARS-CoV-2 in the airways(Day 7)
- Autoantibodies against type I IFNs in the airways(Day 0)
- Lectin complement pathway(Day 7)
- Respiratory pathogens(Day 7)
- Ribosomal RNA in the airways(Day 7)
- Surfactant in the airways(Day 0)